Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upDavid Planchard, Solange Peters, Sanjay Popat et al.|Annals of Oncology|2018Cited by 2.3k
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upLizza Hendriks, Martin Reck, Keith M. Kerr et al.|Annals of Oncology|2023Cited by 782
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 293
Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysisN.E. Verstegen, Suresh Senan, J. Wolter Oosterhuis et al.|Annals of Oncology|2013Cited by 274
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 224